Assenagon Asset Management S.A. Sells 6,155,608 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Assenagon Asset Management S.A. lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 73.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,172,748 shares of the company’s stock after selling 6,155,608 shares during the quarter. Assenagon Asset Management S.A. owned about 0.19% of Teva Pharmaceutical Industries worth $67,811,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of TEVA. 180 Wealth Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth approximately $260,000. Wealth Enhancement Advisory Services LLC grew its position in shares of Teva Pharmaceutical Industries by 3.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock valued at $382,000 after purchasing an additional 379 shares during the last quarter. Grove Bank & Trust increased its stake in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares during the period. Magnus Financial Group LLC lifted its holdings in Teva Pharmaceutical Industries by 27.8% during the 4th quarter. Magnus Financial Group LLC now owns 37,874 shares of the company’s stock worth $1,182,000 after purchasing an additional 8,235 shares during the last quarter. Finally, Union Bancaire Privee UBP SA lifted its holdings in Teva Pharmaceutical Industries by 3,831.4% during the 4th quarter. Union Bancaire Privee UBP SA now owns 786,272 shares of the company’s stock worth $23,733,000 after purchasing an additional 766,272 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $29.19 on Wednesday. The stock has a fifty day moving average price of $32.51 and a 200-day moving average price of $27.27. The company has a market cap of $33.56 billion, a price-to-earnings ratio of 24.33, a PEG ratio of 9.63 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the business earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 1,127 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $35,692.09. Following the transaction, the insider directly owned 10,914 shares of the company’s stock, valued at $345,646.38. This trade represents a 9.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard Daniell sold 17,295 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the transaction, the executive vice president owned 85,755 shares of the company’s stock, valued at $2,715,860.85. The trade was a 16.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 920,901 shares of company stock valued at $30,056,789. Company insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on TEVA. Barclays upped their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Jefferies Financial Group upped their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.